Browse by author
Lookup NU author(s): Dr Anna Walaszczyk,
Dr Rachael Redgrave,
Dr Simon Tual-Chalot,
Professor Ioakim Spyridopoulos,
Dr Andrew Owens,
Professor Helen Arthur,
Dr Joao Passos,
Dr Gavin Richardson
This is the authors' accepted manuscript of a conference proceedings (inc. abstract) that has been published in its final definitive form by Heart , 2018.
For re-use rights please refer to the publisher's terms and conditions.
Ageing is the biggest risk factor for impaired cardiovascular health, cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated not only with an increased prevalence of cardiovascular disease but also with a poorer prognosis, including increased mortality or incidence of heart failure after myocardial infarction (MI).We have demonstrated that aged (23 month old) mice have an accumulation of cardiomyocyte senescence, reduced regenerative potential and display increased mortality as well as impaired recovery following MI. Cellular senescence is defined not only by the irreversible loss of division potential but also by the production of a senescence-associated secretory phenotype (SASP). This cocktail of pro-inflammatory cytokines, chemokines, matrix proteases and growth factors can impact on tissue function, inducing fibrosis, extracellular matrix degeneration and driving inflammation. We have therefore begun to test if clearance of senescent cardiomyocytes, using the senolytic compound Navitoclax, has the potential to improve cardiac health and post MI outcomes in aged animals. Following treatment with Navitoclax, but prior to MI, aged mice demonstrated a reduction in senescent cardiomyocytes which was associated increased cardiomyocyte generation, a decline in myocardial hypertrophy and a decrease in fibrosis. Following MI, Navitoclax treated mice displayed a tendency towards improved survival and had a significant improvement in cardiac function when compared to vehicle controls.We conclude that clearance of senescent cells is a potential therapeutic strategy for the treatment of age related cardiac dysfunction.
Author(s): Walaszczyk A, Dookun ER, Redgrave R, Tual-Chalot S, Anderson R, Spyridopoulos I, Owens A, Arthur H, Passos J, Richardson GD
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: BAS/BSCR Spring Meeting 2018
Year of Conference: 2018
Print publication date: 01/06/2018
Online publication date: 01/06/2018
Acceptance date: 21/02/2018
Date deposited: 06/08/2018